These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33581599)

  • 21. Antiepileptic drugs: generic versus branded treatments.
    Heaney DC; Sander JW
    Lancet Neurol; 2007 May; 6(5):465-8. PubMed ID: 17434101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review.
    Talati R; Scholle JM; Phung OP; Baker EL; Baker WL; Ashaye A; Kluger J; Coleman CI; White CM
    Pharmacotherapy; 2012 Apr; 32(4):314-22. PubMed ID: 22461121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
    Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
    Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Marson AG; Tudur Smith C
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD001911. PubMed ID: 31318037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Generic drugs in the treatment of epilepsy].
    González de Dios J; Ochoa-Sangrador C; Sempere AP
    Rev Neurol; 2005 Dec 1-15; 41(11):676-83. PubMed ID: 16317637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
    Das S; Jiang X; Jiang W; Ting TY; Polli JE
    Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physicians' attitudes toward generic substitutions of antiseizure drugs in epilepsy.
    Olsson P; Freij J; Compagno Strandberg M; Adelöw C; Östlund H; Lindberger M; Källén K
    Acta Neurol Scand; 2021 Nov; 144(5):600-607. PubMed ID: 34273105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brand name to generic substitution of levetiracetam in patients with epilepsy.
    Gha-Hyun L; Dae SJ
    Seizure; 2018 Aug; 60():127-131. PubMed ID: 29960217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
    Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
    Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding authorized generics-A review of the published clinical data.
    Alderfer J; Hansen RA; Mattingly TJ
    J Clin Pharm Ther; 2021 Dec; 46(6):1489-1497. PubMed ID: 33829528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shortages of antiseizure medications in Australia and the association with patient switching, and adherence in a community setting.
    Welton J; Stratton G; Schoeninger B; Low MH; Moody A; D'Souza W
    Epilepsy Behav; 2023 Apr; 141():109145. PubMed ID: 36913876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Bialer M
    Epilepsia; 2007 Oct; 48(10):1825-32. PubMed ID: 17850324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.
    Bosak M; Słowik A; Turaj W
    Drug Des Devel Ther; 2017; 11():2287-2291. PubMed ID: 28814836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Brand-name drugs and generics in the treatment of epilepsy: recommendations of the Russian Antiepileptic League].
    Avakian GN; Belousova ED; Burd SG; Vlasov PN; Gekht AB; Guzeva VI; Zavadenko NN; Zenkov LR; Karlov VA; Petrukhin AS;
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(5 Pt 2):23-5. PubMed ID: 23120785
    [No Abstract]   [Full Text] [Related]  

  • 35. Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations.
    Shin JW; Chu K; Jung KH; Lee ST; Moon J; Lee SK
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1017-22. PubMed ID: 25295717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
    Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY
    Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Barriers to generic antiseizure medication use: Results of a global survey by the International League Against Epilepsy Generic Substitution Task Force.
    Niyongere J; Welty TE; Bell MW; Consalvo D; Hammond C; Leung H; Patsalos PN; Ryan M; Suansanae T; Zhou D; Zuellig H
    Epilepsia Open; 2022 Jun; 7(2):260-270. PubMed ID: 35124903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy.
    Das S; Pu X; Jiang X; Jiang W; Tung R; Ting TY; Polli JE
    Epilepsy Behav; 2019 Jan; 90():197-203. PubMed ID: 30579779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching.
    Margolese HC; Wolf Y; Desmarais JE; Beauclair L
    Int Clin Psychopharmacol; 2010 May; 25(3):180-2. PubMed ID: 20216221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.